Anthracycline resistance in childhood leukemia

G. J.L. Kaspers*, E. Klumper, R. Pieters, A. J.P. Veerman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Clinical resistance to anthracyclines, and the cardiotoxicity associated with the use of the conventional drugs daunorubicin (DNR) and doxorubicin (DOX), initiated the search for new analogues and structurally related drugs. We, use the cell culture drug resistance MTT assay to study the in vitro cytotoxicity of anthracyclines in childhood leukemia. Here, we summarize our results regarding these agents. We also report that relapsed ALL samples were significantly more resistant to DNR, DOX, and mitoxantrone (MIT) than untreated ALL samples, while the antileukemic activity of idarubicin (IDR) and especially of aclarubicin (ACR) was not significantly decreased in relapsed ALL.

Original languageEnglish
Pages (from-to)S158-S159
JournalBone Marrow Transplantation
Volume12
Issue numberSUPPL. 4
Publication statusPublished - 1993

Cite this